News for Healthier Living

GEMMABio Announces Clinical Trial Authorization for New SMA1 Gene Therapy

Gemma Biotherapeutics ("GEMMABio"), a leading global genetic medicines company, announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) is cleared for clinical trial by ANVISA, the health regulatory agency in Brazil.

November 24, 2025


December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025

November 27 2025

November 26 2025

November 25 2025

November 24 2025

November 23 2025

November 22 2025

November 21 2025

November 20 2025

November 19 2025

November 18 2025